NCT04971291View on ClinicalTrials.gov

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
Major Depressive DisorderTreatment Resistant Depression
Interventions
DRUG

AXS-05

AXS-05 taken twice daily for 6 weeks

DRUG

Bupropion SR

Bupropion taken twice daily for 6 weeks

Trial Locations (1)

10007

Axsome Research Site, New York

Sponsors
All Listed Sponsors
lead

Axsome Therapeutics, Inc.

INDUSTRY